| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
BRIEF REPORT |
Department of Microbiology and Immunology (M.S., P.B., P.V.K., B.S.P.), College of Medicine, University of Illinois at Chicago, Chicago, Illinois 60612; Department of Internal Medicine, Endocrinology and Metabolism, and Biochemistry (T.P., F.P.), Section of Endocrinology and Metabolism, University of Siena, 53100 Siena, Italy; and Department of Pathology (Y.E.N.), University of Pittsburgh, Pittsburgh, Pennsylvania 15260
Address all correspondence and requests for reprints to: Bellur S. Prabhakar, Ph.D., Department of Microbiology and Immunology, Room E 705 (MC 790), 835 South Wolcott Avenue, Chicago, Illinois 60612. E-mail: bprabhak{at}uic.edu.
Aim: The aim of the study was to investigate the expression and function of the IG20 gene in thyroid cancer cell survival, proliferation, and apoptosis.
Methods: We determined the expression levels of the major isoforms of IG20 by quantitative RT-PCR in normal and thyroid tumor tissues/cell lines. We evaluated the functional consequence of IG20 knockdown in WRO (follicular carcinoma) and FRO (anaplastic carcinoma) thyroid cancer cell lines by measuring spontaneous, TNF
-related apoptosis-inducing ligand (TRAIL), and TNF
-induced apoptosis.
Results: The IG20 gene expression levels were higher in benign and malignant thyroid tumors and in WRO and FRO cells relative to normal tissues. Predominantly, MADD and DENN-SV isoforms of IG20 gene were expressed. IG20 knockdown resulted in increased spontaneous, TRAIL-, and TNF
-induced apoptosis in WRO, but not FRO, cells. FRO cell resistance to apoptosis is likely due to caspase-8 deficiency.
Conclusion: IG20 knockdown renders WRO cells more susceptible to spontaneous, TRAIL-, and TNF
-induced apoptosis and thus demonstrates the prosurvival function of the IG20 gene in thyroid cancer. These observations, combined with overexpression of IG20 noted in thyroid tumor tissues, may suggest a potential role in thyroid cancer survival and growth and indicate that IG20 may be targeted either alone or in conjunction with TRAIL or TNF
treatment in certain thyroid cancers.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |